The Virginia Catalyst, also known as the Virginia Biosciences Health Research Corporation (VBHRC), today announced that it has awarded $3.18 million in grants to four life and bioscience projects in the Commonwealth of Virginia. These grants, which will be met with significant matching funds from partner companies, were awarded through Grant Round 16.
“Powerful collaborations between Virginia’s research universities and industry is resulting in major breakthroughs in medical diagnostics, devices, and drug discovery” said Mike Grisham, CEO of Virginia Catalyst. “It’s also generating significant
Through this 16th round of funding, Virginia Catalyst has awarded 65 grants totaling nearly $33 million, resulting in over $50 million in matching funds and over $600 million in follow-on funding to date.
Grant Round 16 awarded projects:
Project: Readmission Risk Assessment through Physiological and Behavioral Health Monitoring using
VitalStream Wireless Platform
- Company: Caretaker Medical (Charlottesville, VA)
- University collaborators: University of Virginia and Virginia Tech
- Funding amount: $800,000
Project: Optimization and Commercialization of PRECYSE as a Novel Quality Control Solution for Next Generation Sequencing
- Company: Evizia, Inc. (Charlottesville, VA)
- Funding amount: $800,000
- University collaborators: Virginia Commonwealth University and University of Virginia
Project: Developing an exercise-mimetic to treat diabetes
- Company: MGMedicine, Inc. (Charlottesville, VA)
- University collaborators: University of Virginia and Virginia Tech
- Funding amount: $780,000
Project: First-in-Class Bifunctional Cytokine to Target Tissue Resident Tregs for the Treatment of Idiopathic Nephropathy and other Autoimmune Diseases
- Company: SlateBio, Inc. (Charlottesville, VA)
- University collaborators: University of Virginia and Virginia Commonwealth University
- Funding amount: $800,000